|
"A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)"
|
Ongoing
|
MBG453 (sabatolimab)
|
3
|
CMBG453B12301
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP).
|
Completed
|
Riociguat
|
2
|
BAY 63-2521 / 13605
|
KFMC
|
|
A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy, compared to each monotherapy, for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis (ELIVATE).
|
Ongoing
|
LJN452
|
2b
|
CLJN452D12201C
|
King Fahad Medical City (Riyadh)
|
|
A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin - RADIANT-4
|
Completed
|
RAD001 (Everolimus, Afinitor)
|
3
|
CRAD001T2302
|
KFSH & RC-R
|
|
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma
|
Completed
|
Rituximab / SAIT101
|
3
|
AGB 002
|
PSMMC
|
|
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis
|
Completed
|
Dimethyl fumarate and PEGylated Interferon Beta-1a
|
3
|
800MS301
|
KKUH
|
|
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
|
Ongoing
|
ofatumumab
|
3
|
COMB157G2301
|
KFSH&RC-J
|
|
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)
|
Ongoing
|
Budesonide, Glycopyrronium and Formoterol Fumarate
|
3
|
D5982C00008
|
King Abdulaziz University Hospital (Jeddah)
|
|
A randomized, double-blind placebo-controlled trial to evaluate the safety and efficacy of a SARS-CoV-2 inactivated vaccine among healthcare workers in Saudi Arabia
|
Rejected
|
SARS-CoV-2 inactivated vaccine (Candidate vaccine) - Sinovac
|
3
|
RC20/370/R
|
King Abdulaziz Medical City NG (Riyadh)
|
|
"A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2"
|
Terminated
|
BAY 80-6946/Copanlisib
|
3
|
BAY 80-6946 / 17322
|
KAUH-J
|
